When it comes to reaching markets in the Middle East and North Africa (MENA), global pharmaceutical companies have historically had to contend with fragmented and inefficient systems, stifling their ability to reach patients. However, the Kingdom of Saudi Arabia is hoping it can strengthen a reputation for itself as a reliable life sciences partner with a growing market. Financial inducements, regulatory improvements and infrastructure enhancements are some tools leaders are using to attract more international biopharma investment.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?